|
CCS/HCS/SB 161 - Under this act, the Oversight Division of the Joint Committee on Legislative Research must conduct an actuarial analysis of the cost impact to consumers, health insurers, and other private and public payers if a state mandate was enacted to provide health benefit plan coverages for: (1) Orally administered anticancer medications charged at the same out-of-pocket cost as intravenously administered or injected cancer medications; (2) Diagnosis and treatment of certain eating disorders that include residential treatment and access to psychiatric and medical treatments. Under the terms of the act, the division director must submit a report of the actuarial findings to the Speaker of the House of Representatives, President Pro Tem of the Senate, and the chair of the House Special Committee on Health Insurance and the Senate Small Business, Insurance and Industry Committee by December 31, 2013. The actuarial analysis shall assume that the mandated coverage will not be subject to any greater deductible or copayment than other health care services provided under a health benefit plan and will not apply to a supplemental insurance policy. The cost for each actuarial analysis cannot exceed $30,000 and the division may utilize any actuary contracted to perform services for the Missouri Consolidated Health Care Plan to perform the analysis required under the act. The provisions regarding the actuarial analysis expire December 31, 2013 (Section 376.1192). This provision is also contained in HCS/SS/SB 262 (2013). STEPHEN WITTE
|
